Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of “Moderate Buy” from Analysts

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has received a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $13.75.

A number of equities research analysts recently commented on VYGR shares. Wall Street Zen upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reissued a “sell (d)” rating on shares of Voyager Therapeutics in a research note on Wednesday, October 8th. HC Wainwright decreased their price target on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, November 12th. Finally, Wedbush reaffirmed an “outperform” rating and set a $8.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, November 11th.

Voyager Therapeutics Stock Performance

Shares of VYGR opened at $3.67 on Wednesday. The stock has a market capitalization of $204.05 million, a P/E ratio of -1.70 and a beta of 1.28. Voyager Therapeutics has a 1 year low of $2.64 and a 1 year high of $5.96. The company’s fifty day moving average is $4.09 and its two-hundred day moving average is $4.03.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Monday, November 10th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.06. The company had revenue of $11.15 million during the quarter, compared to analysts’ expectations of $7.86 million. Voyager Therapeutics had a negative net margin of 404.85% and a negative return on equity of 48.94%. Sell-side analysts predict that Voyager Therapeutics will post -0.91 EPS for the current year.

Hedge Funds Weigh In On Voyager Therapeutics

A number of large investors have recently made changes to their positions in the stock. Privium Fund Management B.V. lifted its stake in Voyager Therapeutics by 16.6% in the 2nd quarter. Privium Fund Management B.V. now owns 25,241 shares of the company’s stock valued at $79,000 after buying an additional 3,596 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in Voyager Therapeutics by 9.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 61,775 shares of the company’s stock worth $249,000 after buying an additional 5,422 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Voyager Therapeutics by 5.1% in the second quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock worth $430,000 after acquiring an additional 6,748 shares during the last quarter. Jain Global LLC lifted its position in shares of Voyager Therapeutics by 44.1% in the third quarter. Jain Global LLC now owns 28,104 shares of the company’s stock valued at $131,000 after acquiring an additional 8,600 shares in the last quarter. Finally, AXQ Capital LP boosted its stake in shares of Voyager Therapeutics by 47.8% during the third quarter. AXQ Capital LP now owns 27,360 shares of the company’s stock valued at $128,000 after acquiring an additional 8,844 shares during the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.